Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 3/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14333772 | 0.89 | SMN1; SMN2 (0.53) | MEN1KMT2AALDH1A1PKMHTT | |
| SCHEMBL14992892 | 0.86 | SMN1; SMN2 (0.47) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL14334349 | 0.84 | KEAP1 (0.48) | ALDH1A1L3MBTL1HTTSMN1; SMN2NPY1R | |
| SCHEMBL15819472 | 0.83 | HTT (0.50) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3258403 | 0.83 | NPY1R (0.42) | PKMHTTSMN1; SMN2NPY1RNPY5R | |
| SCHEMBL3257844 | 0.83 | SMN1; SMN2 (0.44) | MEN1KMT2AALDH1A1PKMHTT | |
| SCHEMBL3253962 | 0.83 | GAA (0.44) | ALDH1A1HTTSMN1; SMN2NPY1RNPY5R | |
| SCHEMBL4515544 | 0.82 | CYP19A1 (0.46) | CYP19A1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4496515 | 0.82 | CYP19A1 (0.46) | CYP19A1MEN1KMT2AALDH1A1PKM | |
| SCHEMBL15841261 | 0.82 | HTT (0.48) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029855-A1 | Quinoline Derivatives and Their Use as Pesticides | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-2007727-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS PESTICIDES | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007104726-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS PESTICIDES | BASF SE (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029855-A1 | Quinoline Derivatives and Their Use as Pesticides | CBR3, HCRTR1, HCAR3 | CYP19A1 1573/4885MEN1 2744/4885KMT2A 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.